Research programme: AOC3 protein antagonists - La Jolla Pharmaceutical
Alternative Names: LJP-1207; LJP-1586Latest Information Update: 25 Aug 2022
At a glance
- Originator La Jolla Pharmaceutical Company
- Class Benzylamines; Small molecules
- Mechanism of Action AOC3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation; Multiple sclerosis; Rheumatoid arthritis; Stroke; Ulcerative colitis